Aurobindo Pharma Sees Sharp Open Interest Surge Amid Bullish Momentum

Open Interest and Volume Dynamics

On 3 July 2026, Aurobindo Pharma’s open interest (OI) in derivatives rose sharply by 3,216 contracts, a 10.93% increase from the previous day’s 29,417 to 32,633. This uptick in OI was accompanied by a volume of 34,880 contracts, indicating robust trading activity. The futures segment alone accounted for a value of approximately ₹29,687 lakhs, while options contributed a staggering ₹2,865.62 crores, culminating in a total derivatives value of ₹35,795.5 lakhs.

The underlying stock price closed at ₹1,632, having touched an intraday high of ₹1,636.8, marking a new 52-week peak. This price movement outperformed the Pharmaceuticals & Biotechnology sector by 3.09% and the broader Sensex by 4.22% on the day, reflecting strong relative strength.

Market Positioning and Sentiment

The surge in open interest alongside rising volumes typically suggests fresh positions being established rather than existing ones being squared off. In Aurobindo Pharma’s case, the increase in OI coupled with a price rise points towards bullish positioning by market participants. Traders appear to be betting on continued upward momentum, supported by the stock trading above all major moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — which is a classic technical indicator of strength.

However, it is noteworthy that delivery volumes have fallen sharply by 78.13% to 3.18 lakh shares on 2 July compared to the 5-day average, signalling a decline in investor participation at the delivery level. This divergence between derivatives activity and delivery volumes may indicate that short-term traders and institutional participants are driving the current momentum rather than retail investors holding shares for the long term.

Mojo Score and Analyst Ratings

Aurobindo Pharma currently holds a mojo score of 62.0, categorised as a 'Hold' rating, a downgrade from its previous 'Buy' grade on 25 May 2026. This adjustment reflects a more cautious stance amid evolving market conditions and valuation considerations. The company remains a mid-cap with a market capitalisation of ₹92,957 crores, firmly positioned within the Pharmaceuticals & Biotechnology sector.

Despite the downgrade, the stock’s recent price performance has been impressive, registering a 5.13% gain over the last two consecutive trading sessions. This outperformance relative to its sector peers suggests that the market is pricing in positive near-term catalysts, possibly linked to operational improvements or favourable regulatory developments.

Technical and Liquidity Considerations

From a technical perspective, Aurobindo Pharma’s price trading above all key moving averages signals a strong uptrend. The stock’s liquidity profile remains healthy, with the ability to support trade sizes up to ₹7.23 crores based on 2% of the 5-day average traded value. This liquidity ensures that institutional investors can enter or exit positions without significant price impact, which is crucial for sustained momentum.

However, the sharp decline in delivery volumes warrants attention. It may imply that while derivatives traders are actively positioning, longer-term investors are less engaged, potentially increasing volatility in the near term as speculative activity dominates.

Implications for Investors and Traders

The surge in open interest and volume in Aurobindo Pharma’s derivatives market suggests that traders are increasingly optimistic about the stock’s near-term prospects. The fresh 52-week high and sustained gains over consecutive sessions reinforce this bullish narrative. However, the downgrade in mojo grade and falling delivery volumes introduce a note of caution, signalling that the rally may be driven more by short-term speculative flows than broad-based investor conviction.

Investors should closely monitor the evolution of open interest and price action in the coming sessions. A sustained increase in OI accompanied by rising prices would confirm strong bullish positioning, while any divergence or sharp declines could indicate profit-taking or a potential reversal.

Given the mid-cap status and sector dynamics, Aurobindo Pharma remains an important stock to watch within the Pharmaceuticals & Biotechnology space, especially as the sector navigates regulatory challenges and growth opportunities.

Conclusion

Aurobindo Pharma’s recent open interest surge in derivatives, combined with its price breakout to a new 52-week high, highlights a growing bullish sentiment among traders. While the mojo grade downgrade and reduced delivery volumes suggest some caution, the technical strength and liquidity profile support the possibility of further upside. Market participants should weigh these factors carefully, balancing the potential for gains against the risks of increased volatility driven by speculative positioning.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today